Matthew Campbell Journalist Profile

Articles

Novel Agents/Combinations for aRCC

Jul 31, 2024 | newsbreak.com | Matthew Campbell

Welcome to NewsBreak, an open platform where diverse perspectives converge. Most of our content comes from established publications and journalists, as well as from our extensive network of tens of thousands of creators who contribute to our platform. We empower individuals to share insightful viewpoints through short posts and comments.
New formulations for current therapies – SC vs. IV

Jul 31, 2024 | targetedonc.com | Matthew Campbell |Rana R. McKay

July 31, 2024By The panelists examine the CheckMate-67T study, which evaluated the efficacy and safety of subcutaneous versus intravenous administration of nivolumab in patients with previously treated advanced or metastatic clear cell renal cell carcinoma. CheckMate-67T compared subcutaneous vs intravenous nivolumab in patients with previously treated advanced or metastatic ccRCC. (George et al.
Novel Agents/Combinations for aRCC

Jul 31, 2024 | targetedonc.com | Matthew Campbell |Rana R. McKay

July 31, 2024By Matthew Campbell, MD, MS, and Rana McKay, MD, conclude by addressing the remaining unmet needs and persistent treatment challenges faced in managing patients with advanced renal cell carcinoma. What are some unmet needs and ongoing treatment challenges in patients with advanced RCC? Are there any novel agents or combinations you wish to mention? HIF2α inhibitor – (Pal SK, et al. 2024 ASCO Annual Meeting. Abstract 4513). HIF2α inhibitor – (Bauer TM, et al. 2024 ASCO Annual Meeting.
Advice for Community Oncologists for Treatment Selection for Advanced RCC

Jul 24, 2024 | targetedonc.com | Matthew Campbell |Rana R. McKay

July 24, 2024By Matthew Campbell, MD, MS, and Rana McKay, MD, provide guidance to community oncologists on choosing between immunotherapy combination (IO/IO) and immunotherapy plus tyrosine kinase inhibitor (IO/TKI) regimens for patients with advanced renal cell carcinoma. What advice can you share with community oncologists regarding the selection of an IO/IO or IO/TKI regimen for advanced RCC? Related Content Related Content
Discontinuation or Continuation of IO Therapy – IO/IO vs. IO/TKI Regimens

Jul 10, 2024 | targetedonc.com | Matthew Campbell |Rana R. McKay

July 10, 2024By Dr. Campbell evaluates the efficacy and safety results from the 55-month analysis of the CheckMate-9ER trial, and explores the considerations for discontinuing or continuing immunotherapy (IO) in IO/IO versus IO/TKI combination regimens. Dr Campbell: Please briefly review key efficacy and safety data from the CheckMate-9ER trial 55 month analysis (Bourlon MT, et al. 2024 ASCO Annual Meeting. Abstract 362).
Review of KEYNOTE-426: Five-year Follow-up Data

Jul 10, 2024 | targetedonc.com | Matthew Campbell |Rana R. McKay

July 10, 2024By The key opinion leaders examine the data from the KEYNOTE-426 trial, focusing on safety and efficacy outcomes along with other pertinent updates. Dr McKay: Please briefly review key efficacy and safety data from the KEYNOTE-426 trial 5-year final analysis (Plimack et al. Eur Urol. 2023)? What are the clinical implications of these data for treatment-naïve patients with advanced RCC?
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy - Nature Communications

Jul 4, 2024 | nature.com | Sang T. Kim |Sattva Neelapu |Amishi Y. Shah |Matthew Campbell |don gibbons |Tina Cascone | +10 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-022-29539-3, published online 12 April 2022In this article the funding information for Jordan Kramer was omitted and should have read, ‘J.K. is supported by the CPRIT Research Training Award CPRIT Training Program (RP210028)’. The original article has been corrected.
Current treatment options for ccRCC based on patient and disease factors

Jun 26, 2024 | targetedonc.com | Matthew Campbell |Rana R. McKay

June 26, 2024By Matthew Campbell, MD, MS, and Rana McKay, MD, offer a concise review of existing treatment approaches for clear cell renal cell carcinoma across risk categories, along with considerations for sequencing therapies. Dr Campbell: Please provide a brief overview of current treatment options available to intermediate/poor risk and favorable risk ccRCC. What patient and/or disease factors do you consider when choosing appropriate treatment? Related Content Related Content
CheckMate-214: Long-term follow-up data

Jun 26, 2024 | targetedonc.com | Matthew Campbell |Rana R. McKay

Patient Considerations for Using Dual Immunotherapy for RCCDuring a Case-Based Roundtable® event, Nizar M. Tannir, MD, discussed the importance of site of metastasis and other factors in the use of nivolumab plus ipilimumab in renal cell carcinoma in the first article of a 2-part series.
Scratching the Surface in Managing Advanced RCC

May 19, 2024 | cancernetwork.com | Matthew Campbell

May 19, 2024ONCOLOGY® CompanionONCOLOGY® Companion, Volume 38, Supplement 5Matthew T. Campbell, MD, MS, discusses CAR T-cell therapy and immunotherapy advances in renal cell carcinoma. As part of an Around the Practice program hosted by CancerNetwork, Campbell spoke about recent advancementsin therapeutic strategies for patients with advanced renal cellcarcinoma (RCC).